Therapeutic rationale of combining therapy with gemfibrozil and simvastatin

Journal of the American Pharmacists Association

Volumn 47, Issue 2, 2007, Pages 140-146

  Curtin, Patrick O ^a   Jones, William N ^b,c  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b Pharmacy Benefits Management Strategic Healthcare Group   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

Adult treatment panel III; Adverse drug effects; Dyslipidemias; Gemfibrozil; Rhabdomyolysis; Statins

Indexed keywords

ANTILIPEMIC AGENT; GEMFIBROZIL; SIMVASTATIN;

ARTICLE; CLINICAL PRACTICE; DRUG COMBINATION; FEMALE; HUMAN; HYPERLIPIDEMIA; MALE; MIDDLE AGED; PRACTICE GUIDELINE;

ANTILIPEMIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GEMFIBROZIL; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; SIMVASTATIN;

EID: 34347268771     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/EN88-W778-261P-3134     Document Type: Article

References (23)

1. Scandinavian Simvastatin Survival Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.
2. Shepherd J, Cobb SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study. N Engl J Med. 1995;333:1301-7.
3. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410-8.
4. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-22.
5. The Long Term Intervention With Pravastatin In Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-57.
6. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) Study. Circulation. 2000;102:21-7.
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7-22.
8. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 1998;97:1440-5.
9. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
10. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-47.
11. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79:8-15.
12. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998;81:7B-12B.
13. Assman G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J. 1998;19(suppl M):M8-14.
14. Duell PB, Connor WE, Illingworth DR. Rhabdomyolysis after atorvastatin with gemfibrozil. Am J Cardiol. 1998;81:368-9.
15. Van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, Van Doormaal JJ. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. J Intern Med. 1996;240:403-4.
16. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother. 2002;36:288-95.
17. Zocor [package insert]. Whitehouse Station, N.J.: Merck; 2002.
18. Taher TH, Dzavik V, Reteff EM, et al. Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events. Am J Cardiol. 2002;89:390-4.
19. Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol. 1997;80:608-13.
20. Ellen RL, McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol. 1998:81(suppl):60B-65B.
21. Murdock DK, Murdock AK, Murdock RW, et al. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. Am Heart J.1999;138:151-5.
22. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97(suppl):52C-60C.
23. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-39.